PMID- 32257208
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 12
IP  - 5
DP  - 2020 May
TI  - Corticosteroids alleviate adverse events associated with enzalutamide in patients 
      with metastatic castration-resistant prostate cancer.
PG  - 495-500
LID - 10.3892/mco.2020.2013 [doi]
AB  - The aim of the present study was to investigate the impact of the combined use of 
      corticosteroid on adverse events (AEs) induced by enzalutamide (Enz) in patients 
      with metastatic castration-resistant prostate cancer (mCRPC). The cohort of the 
      present study included 121 consecutive patients with mCRPC who sequentially 
      received androgen receptor-axis-targeted (ARAT) agents, abiraterone acetate (AA) 
      and Enz, in any order, without prior docetaxel therapy. Detailed assessments of 
      AEs during treatment with Enz were conducted according to whether or not 
      corticosteroid was administered. Of these patients, 63 and 58 received ARAT 
      therapy with the Enz-to-AA sequence (group 1) and the AA-to-Enz sequence (group 
      2), respectively. No patient in group 1 received corticosteroid during treatment 
      with Enz, while corticosteroid was continuously administered in combination with 
      Enz to all patients in group 2 following AA failure. When ARAT therapy was 
      initiated, no significant differences in the major baseline characteristics were 
      observed between the two groups. During Enz therapy, there were no significant 
      differences in the incidence of any AEs or AEs >/= grade 3 between the two groups. 
      However, the incidences of fatigue and appetite loss in group 1 were 
      significantly higher when compared with those in group 2. Furthermore, the 
      combined use of corticosteroid was revealed to be independently associated with 
      the prevention of fatigue and appetite loss during Enz therapy. The results of 
      the present study suggested that the combined use of corticosteroids could reduce 
      the incidence of certain types of AE, particularly fatigue and appetite loss, in 
      mCRPC patients treated with Enz.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Tamura, Keita
AU  - Tamura K
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Matsushita, Yuto
AU  - Matsushita Y
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Watanabe, Hiromitsu
AU  - Watanabe H
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Motoyama, Daisuke
AU  - Motoyama D
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Ito, Toshiki
AU  - Ito T
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Sugiyama, Takayuki
AU  - Sugiyama T
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Otsuka, Atsushi
AU  - Otsuka A
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
FAU - Miyake, Hideaki
AU  - Miyake H
AD  - Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, 
      Shizuoka 431-3192, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200305
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC7087477
OTO - NOTNLM
OT  - abiraterone acetate
OT  - adverse event
OT  - corticosteroid
OT  - enzalutamide
OT  - metastatic castration-resistant prostate cancer
EDAT- 2020/04/08 06:00
MHDA- 2020/04/08 06:01
PMCR- 2020/03/05
CRDT- 2020/04/08 06:00
PHST- 2019/08/20 00:00 [received]
PHST- 2020/02/03 00:00 [accepted]
PHST- 2020/04/08 06:00 [entrez]
PHST- 2020/04/08 06:00 [pubmed]
PHST- 2020/04/08 06:01 [medline]
PHST- 2020/03/05 00:00 [pmc-release]
AID - MCO-0-0-2013 [pii]
AID - 10.3892/mco.2020.2013 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2020 May;12(5):495-500. doi: 10.3892/mco.2020.2013. Epub 2020 Mar 
      5.